Capgemini to Enter into a Partnership with IDEMIA for the Launch of a Secure IoT Device Management Platform
28.2.2019 20:08:00 EET | Business Wire | Press release
Capgemini will enter into a new partnership agreement with IDEMIA , the global leader in Augmented Identity, aiming to introduce a secure Internet of Things (IoT) device management platform which reinforces secure connectivity for a vast array of devices and data. This agreement is a step towards meeting the ever-growing need for the connectivity and security of smart objects.
Even though cybercrime costs have quadrupled between 2015 and 20191, IOT will create more opportunities for many industries. Given this context, for IoT to be more scalable and trustworthy for clients and end users, connectivity capabilities and security need to be increased.
Backed by Capgemini and IDEMIA’s expertise, the joint platform intends to bring to smart devices much needed security and connectivity while simplifying the device on-boarding, configuration and integration with existing customer back-end systems. For example, an e-health app gives doctors flexibility in taking care of their patients via an exchange of critical data and provides them with the possibility to make smarter decisions based on authenticated and encrypted devices, secured access (to change parameters) and secure data flow. In the same way, within a factory or across an infrastructure, it enables machines and devices to connect, to predict and prevent fluctuations.
Jean-Pierre Petit, Director of Digital Manufacturing at Capgemini said, “The basic foundation of product or industrial analytics and AI is connectivity coupled with security. Capgemini’s agreement with IDEMIA will provide a unique, fully agnostic, configurable and highly secure platform from an end-point device to the cloud.”
The platform will be based on Capgemini’s IoT device management platform X-IoT, which securely connects and manages any type of gateway and protocols to the cloud, plus IDEMIA’s M-TRUST solution, which guarantees device security of all collected data, command and configurations sent to devices. It can be used for all kinds of devices, from simple smart health devices and smart valves to supply water to a city, through to industrial machinery and devices.
Yves Portalier, Executive Vice-President for Connected Objects activities at IDEMIA said: “We are thrilled to join forces with Capgemini, given the excellent fit of our mutual services. Boosted by our M-TRUST solution, IDEMIA brings its globally reputed expertise to Capgemini with a view to stepping up security for Capgemini’s clients involved in various sectors that are complementary to those we serve.”
About Capgemini
A global leader in consulting, technology
services and digital transformation, Capgemini is at the forefront of
innovation to address the entire breadth of clients’ opportunities in
the evolving world of cloud, digital and platforms. Building on its
strong 50-year heritage and deep industry-specific expertise, Capgemini
enables organizations to realize their business ambitions through an
array of services from strategy to operations. Capgemini is driven by
the conviction that the business value of technology comes from and
through people. It is a multicultural company of over 200,000 team
members in more than 40 countries. The Group reported 2018 global
revenues of EUR 13.2 billion.
Visit us at www.capgemini.com.
People matter, results count.
About IDEMIA
IDEMIA, the global leader in Augmented
Identity, provides a trusted environment enabling citizens and consumers
alike to perform their daily critical activities (such as pay, connect,
travel and vote), in the physical as well as digital space. Securing our
identity has become mission critical in the world we live in today. By
standing for Augmented Identity, an identity that ensures privacy and
trust and guarantees secure, authenticated and verifiable transactions,
we reinvent the way we think, produce, use and protect one of our
greatest assets – our identity – whether for individuals or for objects,
whenever and wherever security matters. We provide Augmented Identity
for international clients from Financial, Telecom, Identity, Public
Security and IoT sectors. With close to $3 billion in revenues and
13,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com /
Follow @IDEMIAGroup on Twitter
1 Source: www.juniperresearch.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005755/en/
Contact information
Capgemini Press contact:
Michele Moore
Tel.:
+44 370 905 3408
E-mail:
michele.moore@capgemini.com
IDEMIA Press Contact:
Hanna SEBBAH
Havas PR
Agency
Email:
idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
